Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial

Related

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Underweight is linked to higher kidney disease risk in diabetes

  Frontiers in Endocrinology · 4 Oct 2026